P7843Safety and efficacy of calcipotriene plus betamethasone dipropionatetopical suspension in adolescents with scalp psoriasis: An open, noncon-trolled, 8-week trial

Melinda Gooderham, MD, Skin Centre for Dermatology and Probity MedicalResearch, Peterborough, Ontario, Canada; Merle Kurvits, MS, LEO Pharma A/S,Ballerup, Denmark; Zhenyi Xu, MD, LEO Pharma A/S, Ballerup, Denmark

Background: About one-third of psoriasis cases present during childhood oradolescence. Most children and adolescents have fairly limited disease and can bemanaged with appropriate use of topical therapies, but the impact on quality of life,self-esteem, school functioning, relationships, and physical and psychologicaldevelopment is significant. Efficacy and safety of the fixed combination ofcalcipotriene plus betamethasone dipropionate topical suspension (C/BD) inplaque psoriasis on body and scalp has been shown in adult patients, but validatedclinical data from treatment of adolescents is limited.

Aims: To investigate the safety and efficacy of C/BD applied once daily for up to 8weeks in adolescents with scalp psoriasis, as the second of 2 separate, parallel trials.

Methods: This was a prospective, noncontrolled, multicenter trial conducted inCanada, France, and the United Kingdom. Subjects aged 12-17 years with moderateto severe scalp psoriasis affecting at least 10% of the scalp area were included. Safetywas the primary objective and was assessed in terms of adverse drug reactions andchange from baseline in serum and urinary calcium. Efficacy assessments includedInvestigator’s Global Assessment of disease severity (IGA), Total Sign Score (TSS;sum of scores for redness, thickness and scaliness), Patient’s Global Assessment ofdisease severity (PaGA), and Patient’s Assessment of Itching.

Results: A total of 78 subjects (35 boys and 43 girls) with a median age of 15 yearswere assigned treatment. Mean extent of psoriasis was 43.7% of the scalp area, and74.4% and 25.6% of subjects had moderate and severe/very severe scalp psoriasis,respectively. Five subjects reported adverse drug reactions and there were noserious adverse events. No cases of hypercalcaemia were reported and there wereno relevant changes in urinary calcium. At end of treatment, 84.6% were clear oralmost clear on the IGA. The mean % improvement in TSS from baseline to end oftreatment was 80.4%. In total, 87.2% of subjects rated their scalp psoriasis as clear orvery mild and 96.2% had no or mild itching compared to 17.9% at baseline.

Conclusions: C/BD topical suspension was well tolerated with no effect on calciummetabolism in adolescents with scalp psoriasis. In this open trial, C/BD appeared tobe highly efficacious as rated by investigators and subjects including a significantimprovement of itching, all of which similar to what has been shown in adults.

AB184

d 100% by LEO Pharma A/S.

Sponsore

P7918Safety of ustekinumab from the placebo-controlled periods of psoriaticarthritis and psoriasis clinical developmental programs

Kim Papp, MD, Probity Medical Research, Waterloo, Ontario, Canada; AlanMendelsohn, MD, Janssen Research & Development, LLC, Spring House, PA,United States; Alice Gottlieb, MD, Tufts Medical Center, Boston, MA, UnitedStates; Daphne Chan, PhD, Janssen Research & Development, LLC, Spring House,PA, United States

Objectives: To describe safety experience of UST during double-blind, PBO-controlled portion of the psoriatic arthritis (PsA) & psoriasis (PsO) clinicalprograms.

Methods: Safety data for PsA population were pooled from 1 Ph2 & 2 Ph3 (PSUMMITI & II) studies in pts with active PsA; for PsO population from 1 Ph2 (n ¼ 320) & 2Ph3 (PHOENIX 1 & 2) studies in pts with moderate to severe PsO, including a sub-grpwith documented PsA (history/current) at baseline (BL). Ptswere randomized toPBO/UST45mg/UST90mg. PBO-controlled period was 16wks for PsA studies, 20wksfor Ph2 PsO study and 12wks for Ph3 PsO studies. Concomitant therapies werepermitted in PsA studies but not in the PsO studies. Safety event rates werecompared between PBO & UST grps within each population (PSA, PSA subgrp,PSO). Data for UST dose grps were analyzed as a combined grp. All pts who received¼ 1 dose were included. Results reported as number of events per 100 pt-yrs offollow-up (PY).

Results: 1071 treated pts (379 PBO [110 PY], 692 UST [209 PY]) were included inPsA population & 2314 treated pts (732 PBO [177 PY], 1582 UST [407 PY]) wereincluded in PsO population (including 207 PBO [49 PY], 421 UST [106 PY] in PsAsub-grp). BL demographics & medical history were generally comparable betweenPsA & PsO populations. Within each population, rates of overall AEs, infections, &SAEs in pts receiving PBO or UST were generally comparable. AEs per 100PY (PBOvs. UST): PsA studies 348.07 vs. 375.83, PsO studies 413.24 vs. 502.91, PsA sub-grp476.42 vs. 481.32. Infections per 100PY (PBO vs. UST): PsA studies 110.59 vs.100.06, PsO studies 142.79 vs. 141.16, PsA sub-grp 139.89 vs. 142.79. A slightlyhigher rate of SAEs was observed in the PBO grp in PsA population; SAEs per 100PY(PBO vs. UST): PsA studies 12.69 vs. 5.75, PsO studies 6.78 vs. 7.62, PsA sub-grp 4.05vs. 6.62. Slightly higher rates of AEs leading to d/c were observed across all PBOgrps; AEs leading to d/c per 100PY (PBO vs. UST): PsA studies 13.79 vs. 3.85, PsOstudies 9.74 vs. 5.95, PsA sub-grp 12.37 vs. 5.71. Serious infections, NMSC, othermalignancies, and MACE were generally comparable, with overlapping confidenceintervals, between the PBO & UST grps within the PsA & PsO populations.

Conclusions: During the PBO-controlled period, overall safety observations wereconsistent between both populations and safety event rates were generally compa-rable between pts receiving PBO and UST within each population.

d 100% by Janssen Research & Development, LLC.

Sponsore

J AM ACAD DERMATOL

P7617Safety profile of ixekizumab, an antieIL-17 monoclonal antibody, inchronic plaque psoriasis patients after at least 1 year of open labeltreatment

Kenneth Gordon, MD, Northwestern University, Feinberg School of Medicine,Chicago, IL, United States; Craig Leonardi, MD, St. Louis University School ofMedicine, St. Louis, MO, United States; Daniel Braun, MD, Eli Lilly and Company,Indianapolis, IN, United States; Gregory Cameron, PhD, Eli Lilly and Company,Indianapolis, IN, United States; Janelle Erickson, PhD, Eli Lilly and Company,Indianapolis, IN, United States; Mark Lebwohl, MD, The Mount Sinai School ofMedicine, New York, NY, United States; Michael Heffernan, MD, Eli Lilly andCompany, Indianapolis, IN, United States; Subhashis Banerjee, MD, Eli Lilly andCompany, Indianapolis, IN, United States

Background: Ixekizumab is a humanized monoclonal antibody that neutralizes IL-17A shown to be effective for treating moderate to severe chronic plaque psoriasisin a phase 2 study. Longer term safety was evaluated with an open-label extension(OLE) of this study with a minimum of 52 additional weeks of treatment.

Methods: In the phase 2 study, 142 pts were randomized to treatment withixekizumab (10, 25, 75, or 150 mg) or placebo at 0, 2, 4, 8, 12, and 16 weeks. Ptswere eligible to enter the OLE at Week 32 or when responses were\ PASI 75. Ptsentering the OLE were treated with 120 mg ixekizumab every 4 weeks. Safety wasassessed by monitoring adverse events (AE), serious AEs (SAE), vital signs, standardlaboratory measures and adverse events of special interest (AESI). In this interimanalysis, safety data is included through 52 weeks for all pts in the OLE. Additionalpreliminary data through week 100 are reported for patients with additionalexposure at the time of the analysis.

Results: Of the 120 ptswho entered the OLE, 103 remained on therapy after 52weeks.Of the 17 pts who discontinued, 4 were for AEs, 2 of which were SAEs (urinary tractobstruction and hidradenitis), and 3 were for lack of efficacy. Therewere 67% pts withtreatment-emergent AEs (TEAEs). Of those occurring in ¼ 2.5% of pts, infections(nasopharyngitis and upper respiratory infections) were the most common and mostweremild tomoderate. Other notable TEAEswere cellulitis (4), urinary tract infections(4), candidiasis (2 oral and 2 vaginal), and injection site reactions (2). Allergicreaction/hypersensitivies were observed in 4 pts. There were 2 reports of Grade 3increase in ALT and no Grade 3 neutropenia. No clinically significant changes wereobserved in vital signs. A total of 13 SAEs were reported for 10 pts. Notable SAEs werecardiac disorders (3: acute coronary syndrome, arteriosclerosis, CHF), cellulitis (1),pyelonephritis (1), rectal cancer (1) and skin disorder (1: hidradenitis).

Conclusions: We report over 1 year of additional safety data from anOLE of a phase 2trial of ixekizumab. To date, ixekizumab has been well tolerated and most AEs weremild to moderate. Five large phase III studies with ixekizumab will provide furtherdata on its long-term safety.

d 100% by Eli Lilly and Company.

Sponsore

P8417Secukinumab autoinjectors demonstrate patient satisfaction: An analysisof the Self-Injection Assessment Questionnaire (SIAQ) in the JUNCTUREStudy

Katharina Kreutzer, MD, St€adtische Kliniken Bielefeld, Bielefeld, Germany; Jean-Philippe Lacour, MD, Dermatology Department, Nice, France; Ruquan You, MS,Beijing Novartis Pharma Co. Ltd., Shanghai, China; Usha G. Mallya, NovartisPharmaceuticals Corporation, East Hanover, NJ, United States

Background: JUNCTURE (NCT01636687) was the first study to test autoinjector(AI)-administered secukinumab (AIN457), a fully human anti-interleukin 17Amonoclonal antibody, in the treatment of plaque-type psoriasis. The study evaluatedthe efficacy of secukinumab (150 and 300 mg) administered subcutaneously (SC)versus placebo at week 12 and the long-term efficacy, safety, and tolerability of thesecukinumab liquidwhen used for 52weeks. Patient satisfactionwas assessedwith aself-administered Self-Injection Assessment Questionnaire (SIAQ).

Methods: JUNCTURE was a randomized, double-blind, placebo-controlled, multi-center, phase 3 study conducted between Oct 2012 and Apr 2013. Subjects wererandomized 1:1:1 to 1 of 3 treatment arms: secukinumab 150 mg or 300 mg SC onceweekly for 4 weeks, then once every 4 weeks from week 4 through week 48, ormatching placebo. Subjects were trained to self-inject via AI and self-administeredthe study drug in the appropriate injection site at the study site (2 injections pervisit). The SIAQ measures overall subject experience with SC self-injection beforethe first self-injection and after dosing on the domains of feelings about injections,self-confidence, satisfaction with self-injection, injection-site reactions, ease of use,and self-image. The SIAQ was completed at baseline and weeks 1, 4, 8, 12, 24, 36,and 48. Subjects rated each item of the SIAQ on a 5-point scale: 1 (worst experience)to 5 (best experience). Scores were transformed to 0 (worst experience) to 10 (bestexperience). Summary statistics for the domain scores and item scores will beprovided by visit and treatment group. Item and domain scores from the moduletaken before the first self-injection at baseline will be compared with those from themodule taken after the 2 self-injections.

Results: SIAQ data were available for 182 subjects. Scores for feelings about self-injections, self-confidence, and satisfaction with self-injections improved frombaseline to week 12 for all groups. Mean absolute increases (baseline to week 12)were 1.00 (7.81 to 8.82), 1.47 (7.40 to 8.88), and 2.35 (6.68 to 9.03), respectively.Results up to week 48 are expected in January 2014 and will be provided in the finalpresentation.

Conclusions: Patient satisfaction with administration mode is an importantconsideration for a chronic disease such as psoriasis. Results from this study suggestusability and patient satisfaction with secukinumab AI in the study subjects.

d by Novartis Pharmaceuticals (100%).

Sponsore

MAY 2014